Welcome home, fellow Gator.

The Gator Nation's oldest and most active insider community
Join today!

Covid-19: Treatments, Cures, and Vaccines

Discussion in 'Too Hot for Swamp Gas' started by exiledgator, Apr 10, 2020.

  1. duchen

    duchen VIP Member

    9,027
    3,240
    1,723
    Nov 25, 2017
    Please post your opinions on the other thread. This is an information thread. Thanks. Monoclonal antibodies are a treatment to prevent severe disease. It is not for you to decide who needs it or who doesn’t. It works to prevent severe disease.
     
    • Like Like x 3
  2. QGator2414

    QGator2414 VIP Member

    11,588
    518
    698
    Aug 24, 2009
    Ocala
    I will continue to respond with my thoughts on these drugs in this information thread. I am sorry you don’t like the responses. Though we agree on some of it.
     
    • Dislike Dislike x 1
    • Winner Winner x 1
  3. Gator715

    Gator715 GC Hall of Fame

    4,251
    671
    478
    Dec 6, 2015
    I already have, care to answer the question, there?
     
  4. duchen

    duchen VIP Member

    9,027
    3,240
    1,723
    Nov 25, 2017
    That isn’t what this thread was for. There is another thread for everyone’s thoughts. This thread is for information.
     
    • Like Like x 1
    • Agree Agree x 1
  5. OklahomaGator

    OklahomaGator Jedi Administrator Moderator VIP Member

    94,367
    96,940
    13,488
    Apr 3, 2007
    This is an example of information that this thread is for. If you want to discuss this, please use the other COVID thread.
     
    • Like Like x 1
    • Fistbump/Thanks! Fistbump/Thanks! x 1
  6. QGator2414

    QGator2414 VIP Member

    11,588
    518
    698
    Aug 24, 2009
    Ocala
    And I was engaged in that. We had a pharmacist ranting about ivermectin. Which can be something doctors use to treat. Some agree with it and others do not. It led to monoclonal antibodies. Thank goodness DeSantis brought them to the forefront so more people were aware of the treatment.

    So sorry you don’t like my thoughts on treatments out there. I will continue to share them and discuss based on how the responses dictate.
     
    • Come On Man Come On Man x 2
    • Off-topic Off-topic x 1
  7. GatorJMDZ

    GatorJMDZ gatorjack VIP Member

    19,232
    1,299
    1,868
    Apr 3, 2007
    Didn't your wife's dental office accept government assistance for small business affected by the pandemic? Why should taxpayers that didn't need help subsidize that?
     
    • Like Like x 1
    • Off-topic Off-topic x 1
  8. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    Johnson & Johnson reporting strong data in support of a booster shot. Very encouraging data to a booster at 2 months, as well as almost equally good data when the booster was provided 6 months after the original shot.

    As I understand the Ad26 vectored vaccine there is always some concern with boosters that the body developed antibodies against the adenovirus before it can deliver the genetic material for the spike protein production to the muscle cells, nullifying any benefit for follow up shots. I guess that was not the case?

    Johnson & Johnson trots out two-dose COVID vaccine data as it builds case for boosters
     
    • Informative Informative x 3
    • Fistbump/Thanks! Fistbump/Thanks! x 1
  9. flgator2

    flgator2 GC Hall of Fame

    2,014
    241
    468
    Apr 3, 2007
    Dr. Marty Makary: Feds' disregard of natural immunity is 'deadly' (wnd.com)

    Among them is a 700,000-person study from Israel released earlier this month that found that those who had experienced prior infections were 27 times less likely to get a second symptomatic COVID-19 infection than those who were vaccinated.

    The finding affirmed a study published in June by the Cleveland Clinic of health-care workers, who are often exposed to the virus. None of the workers who had previously tested positive for the coronavirus got reinfected. The study authors concluded that "individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination." In May, a Washington University study found that even a mild COVID infection resulted in long-lasting immunity.

    "That's why it's so frustrating that the Biden administration has repeatedly argued that immunity conferred by vaccines is preferable to immunity caused by natural infection, as NIH director Francis Collins told Fox News host told Bret Baier a few weeks ago," he said.

    Markary noted the current Centers for Disease Control and Prevention position on vaccinating children dismisses the benefits of natural immunity, ignoring the fact that young people are less likely to suffer severe or long-lasting symptoms from COVID-19 than adults. At the same time, young people have experienced rare heart complications from the vaccines.
     
    • Come On Man Come On Man x 1
  10. swampbabe

    swampbabe GC Hall of Fame

    2,214
    566
    548
    Apr 8, 2007
    Viera, FL
    https://mediabiasfactcheck.com/world-net-daily-
    wnd/

    Where do you find this crap?
     
    • Winner Winner x 1
  11. gatorchamps960608

    gatorchamps960608 GC Legend

    735
    211
    318
    Jul 4, 2020
    We have over 600,000 dead mostly from the red states desire to primarily employ infection-based herd immunity.

    Thanks, but those of us with 3-digit IQs will take the "vaccinate everyone" path that worked for smallpox and polio over more mass death.
     
    • Like x 2
    • Come On Man x 2
    • Dislike x 1
    • Agree x 1
    • Funny x 1
    • Off-topic x 1
  12. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    Coidgenix announces positive safety data from the Phase 1 trial of their intranasal vaccine candidate. This is a "live"-attenuated virus that promotes localized immune responses which in turn blocks replication or the SARS-CoV-2 in the nasal passages. This appears to reduce/eliminate the ability of the virus to get into the upper respiratory system.

    Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies
     
    • Like Like x 1
    • Informative Informative x 1
  13. tilly

    tilly Superhero Mod. Fast witted. Bulletproof posts. Moderator VIP Member

    o_O
     
    • Agree Agree x 1
    • Off-topic Off-topic x 1
  14. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    Chinese Biopharmaceutical company, Clover Biopharmaceuticals, score a major win with their synthetic protien molecule, adjuvanted vaccine. In a Phase 2/3 trial in partnership with CETI, including over 30,000 participants around the world, found that it had an overall efficacy of 67% against infection, but an 79% efficacy against the Delta Variant. The overall number was reduced because 1/4 of the cases recored were infected with Mu variant and the vaccine only showed a 58% efficacy against that variant. The vaccine demonstrated 100% efficacy against severe disease and hospitalization across all strains.

    They are looking to gain WHO approal and start delivering vaccine to COVAX.

    Clover's COVID-19 shot tames delta in pivotal study, delivering boost to global vaccination campaign
     
  15. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    FDA grants Pfizer EUA for a THIRD Shot, AKA 2nd Booster, AKA Booster.....for thos 65+, those who are immunocompromised and those who are high risk for severe disease and front line workers.

    According to CDC statistics, those groups total approximately 165-185 million Americans.....or more than half of the nation's popultion and well more than half of the total eligible American adults.

    FDA authorizes Pfizer's Covid-19 booster for people over 65 or at high risk
     
    • Informative Informative x 1
  16. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    Pfizer launches a Phase 3 trial to study efficacy of its newer oral anti-viral drug, paired with an older drug targeted at HIV (Ritonavir) to use as prophylaxsis for people living with, or in close proximity to those infected with COVID. Phase 3 trials for this drug pair against severe disease and hospitalization, as well as mild to moderate disease are already under way.

    Pfizer tests oral COVID-19 antiviral for preventing infection in people living with patients
     
  17. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    Pfizer submitted the data and EUA application for using its vaccine on children 5-11. Sure there will be some significant debate over this by the CDC advisory panel as some have privately hinted that they do not see the need/value/benefit of vaccinating children that young, while other see this as a chance to break a key link in the chain of community spread from one adult to the household through the child.

    https://www.cnbc.com/2021/09/28/pfi...for-covid-19-vaccine-in-younger-children.html
     
  18. gatorpa

    gatorpa GC Hall of Fame

    7,933
    408
    298
    Sep 5, 2010
    East Coast of FL
    Is that accurate?

    I mean do you have a link to back up your statement
     
    Last edited: Sep 28, 2021
    • Winner Winner x 1
    • Off-topic Off-topic x 1
  19. QGator2414

    QGator2414 VIP Member

    11,588
    518
    698
    Aug 24, 2009
    Ocala
    This is crazy in my opinion. Kids are at almost no risk from the disease. To each their own but I would not advise having kids vaccinated with a new drug for this disease when the benefits are weighed against the risks.
     
    • Agree Agree x 1
    • Winner Winner x 1
    • Off-topic Off-topic x 1
  20. ncargat1

    ncargat1 VIP Member

    7,226
    2,865
    1,618
    Dec 11, 2009
    It would be interesting to have the data, and I wonder if the CDC committee will have any data along these lines, looking at contact tracing cases where children contracted COVID, had little to no symptoms, but then transmitted within the home. To me, this data would be the strongest argument for vaccinating children. I doubt that such detailed data exists at this point however.